Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05451303 · ClinicalTrials.gov registry record
Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
A clinical trial of Oropharynx Squamous Cell Carcinoma and Oral Squamous Cell Carcinoma, sponsored by Viome.
- Recruiting
- Registry status
- 475
- Enrollment target
- 1
- Study location
NCT05451303: Recruiting study of Oropharynx Squamous Cell Carcinoma and Oral Squamous Cell Carcinoma, sponsored by Viome.
NCT05451303 is a study of Oropharynx Squamous Cell Carcinoma and Oral Squamous Cell Carcinoma that is actively recruiting participants, run by Viome. The registered enrollment target is 475 participants, above the 88-participant average among 6 other Oropharynx Squamous Cell Carcinoma trials with a reported enrollment target (440% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05451303, a study of Oropharynx Squamous Cell Carcinoma and Oral Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Viome.
- RECRUITING
- Registry status
- 475 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the design, safety and efficacy of OralViome Cancer Testing system in the early detection of Oral and Throat Cancers using saliva metatranscriptomic analysis. This study will recruit only at existing clinical sites and will NOT use any additional clinical sites.
Primary Outcome
The test results will be compared against the definitive diagnosis by the physician.
Conditions Studied
Interventions
- DEVICE OralViome Cancer Testing System
Study Locations (1)
New York
- NYMC - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 475 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2026-12 |
What NCT05451303 shows while recruiting
NCT05451303 is an observational study that tracks outcomes without assigning an intervention. The registered 475 participants enrollment target is mid-sized for trials with a published cap, above the 88-participant average among 6 other Oropharynx Squamous Cell Carcinoma trials with a reported enrollment target (440% higher).
The record links to 3 conditions, with Oropharynx Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which OralViome Cancer Testing System is the first listed.
NCT05451303 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05451303 about?
NCT05451303 is a clinical study titled "Detection of Oral and Throat Cancers Using OralViome Cancer Testing System". To evaluate the design, safety and efficacy of OralViome Cancer Testing system in the early detection of Oral and Throat Cancers using saliva metatranscriptomic analysis. This study will recruit only at existing clinical sites and will NOT use any additional clinical sites.
What is the current status of trial NCT05451303?
This trial is currently recruiting. The enrollment target is 475 participants. The study started on 2022-05-27. Estimated completion is 2026-12.
What conditions does trial NCT05451303 study?
This clinical trial studies the following conditions: Oropharynx Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Premalignant Lesion.
What interventions are being tested in trial NCT05451303?
The interventions under investigation include: OralViome Cancer Testing System (DEVICE).
Who is sponsoring clinical trial NCT05451303?
This trial is sponsored by Viome, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05451303 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oropharynx Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
RECRUITING · Phase 2
-
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
RECRUITING
-
Training Swallowing Initiation During Expiration
RECRUITING · NA
-
Saliva-based Detection of CD44
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01788839 · 475 participants
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
- NCT06892379 · 475 participants · Phase 1
A Study of HS-20110 in Participants With Advanced Solid Tumors
- NCT06754046 · 476 participants · NA
BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair (BELIEVE)
- NCT05624996 · 474 participants · Phase 3
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI